BTIG, Inari
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
BTIG Chief Market Technician Jonathan Krinsky thinks the market can “continue to make upside progress” into year-end and sees a new all-time high for the S&P 500 (SPX) above 6,100. However ...
BTIG Research has recently reduced Beyond Air Inc (XAIR) stock to Neutral rating, as announced on June 25, 2024, according to Finviz. Earlier, on July 28, 2023, Piper Sandler had initiated the stock ...
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.
BTIG analyst Jake Fuller says that while Uber‘s (UBER) commentary on its U.S. rideshare business “felt constructive” at intra-quarter appearances, the firm’s receipt data was “more ...
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback